Track Sequana Medical NV — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Sequana Medical NV SEQUA.BR Open Sequana Medical NV in new tab

0.6110 EUR
EPS
-1.22
P/B
-0.95
Beta
-0.06
Target Price
3.50 EUR
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 27, 2026
EPS-1.22
Book Value-1.00
Price to Book-0.95
% Insiders21.119%
Growth
Revenue Growth-1.00%
Estimates
Forward P/E-0.79
Forward EPS-1.20
Target Mean Price3.50

DCF Valuation

Tweak assumptions to recompute fair value for Sequana Medical NV (SEQUA.BR)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Sequana Medical NV Logo Sequana Medical NV Analysis (SEQUA.BR)

Belgium Health Care Official Website Stock

Is Sequana Medical NV a good investment? Sequana Medical NV (SEQUA.BR) is currently trading at 0.6110 EUR. Market analysts have a consensus price target of 3.50 EUR. This suggests a potential upside from current levels.

Earnings Schedule: Sequana Medical NV is expected to release its next earnings report on Aug. 27, 2026. The market consensus estimate for Forward EPS is -1.20.

Investor FAQ

Does Sequana Medical NV pay a dividend?

No, it does not currently pay a dividend.

What asset class is Sequana Medical NV?

Sequana Medical NV is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 27, 2026. The company currently has a trailing EPS of -1.22.

Company Profile

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

Exchange Ticker
STU (Germany) 2SE.SG
BRU (Belgium) SEQUA.BR

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion